Last update 16 May 2025

Dapagliflozin/Olmesartan Medoxomil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ATB 101, ATB-101, ATB-1011/ATB-1012
+ [2]
Target
AT1R x SGLT2
Action
antagonists, inhibitors
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic Disease
Active Indication
Essential HypertensionDiabetes Mellitus, Type 2Hypertension
Inactive Indication-
Originator Organization
Autotelic Bio Co. Ltd.
Active Organization
Autotelic Bio Co. Ltd.Firson Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H25ClO6
InChIKeyJVHXJTBJCFBINQ-ADAARDCZSA-N
CAS Registry461432-26-8
View All Structures (2)

Related

2
Clinical Trials associated with Dapagliflozin/Olmesartan Medoxomil
NCT05573477
/ RecruitingPhase 3
A Randomized, Active-controlled, Double-blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated ATB-1011 and ATB-1012 in Patients With Essential Hypertension and Type II Diabetes Mellitus
NCT05017987
/ CompletedPhase 1
A Phase I Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
100 Clinical Results associated with Dapagliflozin/Olmesartan Medoxomil
Login to view more data
100 Translational Medicine associated with Dapagliflozin/Olmesartan Medoxomil
Login to view more data
100 Patents (Medical) associated with Dapagliflozin/Olmesartan Medoxomil
Login to view more data
100 Deals associated with Dapagliflozin/Olmesartan Medoxomil
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Essential HypertensionPhase 3
South Korea
Autotelic Bio Co. Ltd.
16 Nov 2022
Diabetes Mellitus, Type 2Phase 3
South Korea
Autotelic Bio Co. Ltd.
10 Oct 2022
HypertensionPhase 3
South Korea
Firson Co. Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free